These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 8475410)

  • 1. Cellular pharmacodynamics of anticancer drugs.
    Plunkett W; Gandhi V
    Semin Oncol; 1993 Feb; 20(1):50-63. PubMed ID: 8475410
    [No Abstract]   [Full Text] [Related]  

  • 2. [Biochemical basis of the treatment of leukemia with cytosine-arabinoside].
    Wilmanns H
    Schweiz Med Wochenschr; 1970 Feb; 100(7):323-5. PubMed ID: 5413922
    [No Abstract]   [Full Text] [Related]  

  • 3. Cell cycle and drug sensitivity studies of leukemic cells that appear relevant in determining response to chemotherapy in acute nonlymphocytic leukemia.
    Raza A; Maheshwari Y; Mandava N; Yasin Z; Perveen S; Mayers G; Browman G; Goldberg J; Gottlieb A; Grunwald H
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):217-25. PubMed ID: 3589695
    [No Abstract]   [Full Text] [Related]  

  • 4. Intracellular pharmacodynamics in leukemia therapy.
    Gandhi V; Estey EH; Keating MJ; Plunkett W
    Rinsho Ketsueki; 1996 May; 37(5):369-79. PubMed ID: 8691580
    [No Abstract]   [Full Text] [Related]  

  • 5. [Biochemical criteria of the sensitivity of patients with leukosis to 6-mercaptopurine and cytosar].
    Gerasimova GK; Sidorova TA; Volkova MA; Maiakova SA; Golenko OD
    Vestn Akad Med Nauk SSSR; 1984; (5):78-85. PubMed ID: 6540013
    [No Abstract]   [Full Text] [Related]  

  • 6. Cytarabine.
    Betcher DL; Burnham N
    J Pediatr Oncol Nurs; 1990 Oct; 7(4):154-7. PubMed ID: 2081008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Sunrabin for injection].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1983 Sep; 10(9):2077-81. PubMed ID: 6614941
    [No Abstract]   [Full Text] [Related]  

  • 8. [Strategy of chemotherapy of a patient with acute leukemia based on the mechanism of action of drugs].
    Uchida M; Ueda T; Nakamura T
    Rinsho Ketsueki; 1986 Aug; 27(8):1445-53. PubMed ID: 3795516
    [No Abstract]   [Full Text] [Related]  

  • 9. Mechanism of action of cyclocytidine in leukemic cells.
    Nakamura T; Wakisaka G
    Bibl Haematol; 1975; (40):755-6. PubMed ID: 1164408
    [No Abstract]   [Full Text] [Related]  

  • 10. Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells.
    Bouffard DY; Jolivet J; Leblond L; Hamelin B; Ouellet F; Barbeau S; Richard A; Gourdeau H
    Cancer Chemother Pharmacol; 2003 Dec; 52(6):497-506. PubMed ID: 12955470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cytarabine: mechanism of action and clinical application].
    Eridani S
    Haematologica; 1972; 57(7):341-58. PubMed ID: 4628582
    [No Abstract]   [Full Text] [Related]  

  • 12. Brook Lodge Symposium on "The pharmacology of Cytosar-U as it relates to its therapeutic usage". Kalamazoo, Michigan, December 13-15, 1981.
    Med Pediatr Oncol; 1982; 10 Suppl 1():1-272. PubMed ID: 7162457
    [No Abstract]   [Full Text] [Related]  

  • 13. Modeling the pharmacodynamics of highly schedule-dependent agents: exemplified by cytarabine-based regimens in acute myeloid leukemia.
    Braess J; Fiegl M; Lorenz I; Waxenberger K; Hiddemann W
    Clin Cancer Res; 2005 Oct; 11(20):7415-25. PubMed ID: 16243815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYTOSAR-U sterile powder: therapeutic biological effects. Proceedings of a symposium. November 30-December 2, 1986, Kalamazoo, MI.
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):1-275. PubMed ID: 3589683
    [No Abstract]   [Full Text] [Related]  

  • 15. Arsenic suppresses necrosis induced by selenite in human leukemia HL-60 cells.
    Zeng H
    Biol Trace Elem Res; 2001 Oct; 83(1):1-15. PubMed ID: 11693998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
    Nandy P; Lien EJ; Avramis VI
    Anticancer Res; 1999; 19(3A):1625-33. PubMed ID: 10470093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility to cytosine arabinoside (Ara-C)-induced cytotoxicity in human leukemia cell lines.
    Kanno S; Higurashi A; Watanabe Y; Shouji A; Asou K; Ishikawa M
    Toxicol Lett; 2004 Sep; 152(2):149-58. PubMed ID: 15302096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A sensitive new method for clinically monitoring cytarabine concentrations at the DNA level in leukemic cells.
    Yamauchi T; Ueda T
    Biochem Pharmacol; 2005 Jun; 69(12):1795-803. PubMed ID: 15935150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
    Seymour JF; Huang P; Plunkett W; Gandhi V
    Clin Cancer Res; 1996 Apr; 2(4):653-8. PubMed ID: 9816215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Why is the DNA-strand-breaker, PCNDAC, effective to solid tumors?].
    Matsuda A; Sasaki T
    Tanpakushitsu Kakusan Koso; 1998 Oct; 43(13):1981-9. PubMed ID: 9789461
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.